tetano
Editor, Senior Moderator
J Interferon Cytokine Res
. 2021 Nov;41(11):407-414.
doi: 10.1089/jir.2021.0106.
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
Michelle Møhlenberg[SUP] 1 [/SUP], Ida Monrad[SUP] 2 [/SUP], Line K Vibholm[SUP] 2 [/SUP], Stine S F Nielsen[SUP] 2 [/SUP], Giacomo Schmidt Frattari[SUP] 2 [/SUP], Mariane Høgsbjerg Schleimann[SUP] 2 [/SUP], Rikke Olesen[SUP] 2 [/SUP], Mads Kjolby[SUP] 3 4 5 6 [/SUP], Jesper Damsgaard Gunst[SUP] 2 [/SUP], Ole Schmeltz Søgaard[SUP] 2 7 [/SUP], Thomas R O'Brien[SUP] 8 [/SUP], Martin Tolstrup[SUP] 2 7 [/SUP], Rune Hartmann[SUP] 1 [/SUP]
Affiliations
Abstract
Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8[SUP]+[/SUP] T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8[SUP]+[/SUP] T cell responses of these patients.
Keywords: COVID-19; Interferon lambda-4; SARS-CoV-2; T cell response; antibody; genetics.
. 2021 Nov;41(11):407-414.
doi: 10.1089/jir.2021.0106.
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
Michelle Møhlenberg[SUP] 1 [/SUP], Ida Monrad[SUP] 2 [/SUP], Line K Vibholm[SUP] 2 [/SUP], Stine S F Nielsen[SUP] 2 [/SUP], Giacomo Schmidt Frattari[SUP] 2 [/SUP], Mariane Høgsbjerg Schleimann[SUP] 2 [/SUP], Rikke Olesen[SUP] 2 [/SUP], Mads Kjolby[SUP] 3 4 5 6 [/SUP], Jesper Damsgaard Gunst[SUP] 2 [/SUP], Ole Schmeltz Søgaard[SUP] 2 7 [/SUP], Thomas R O'Brien[SUP] 8 [/SUP], Martin Tolstrup[SUP] 2 7 [/SUP], Rune Hartmann[SUP] 1 [/SUP]
Affiliations
- PMID: 34788130
- DOI: 10.1089/jir.2021.0106
Abstract
Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8[SUP]+[/SUP] T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8[SUP]+[/SUP] T cell responses of these patients.
Keywords: COVID-19; Interferon lambda-4; SARS-CoV-2; T cell response; antibody; genetics.